




























Name	Class	Structure	IC50	Target	Clinical development	Reference
<b>Aspirin (NSAIDs)</b>	Generic		29.3 μM	β-catenin	Clinical	(3, 11, 29, 32)
<b>Celecoxib (NSAIDs)</b>	Generic		25 μM	COX2	FDA-approved (Pfizer)	(15, 24, 28)
<b>Sulindac (NSAIDs)</b>	Generic		1.8/ 6.3 μM	COX1, COX2	FDA-approved	(36)
<b>Retinoids (Vitamins)</b>	Generic		-	β-catenin-TCF	Clinical	(31)
<b>1α25,-dihydroxy-Vitamin D3 (Vitamins)</b>	Generic		5.8 nM (COX-2)	β-catenin-TCF	Clinical	(25)
<b>Curcumin (Polyphenols)</b>	Generic		20 μM	Nonspecific antioxidant	-	(18)
<b>EGCG (Polyphenols)</b>	Generic		20 μg/ml	Antioxidant	-	(21,30)
<b>Quercetin (Polyphenols)</b>	Generic		100 μM	Antioxidant	-	(26)
<b>Resveratrol (Polyphenols)</b>	Generic		-	β-catenin-TCF, sirtuin activator, antioxidant	-	(5,10)
<b>IWP-1</b>	Wnt-receptor complex		58 nM	Porcupine	Preclinical	(4)
<b>IWP-2</b>	Wnt-receptor complex		27 nM	Porcupine	Preclinical	(4)
<b>LGK974</b>	Wnt-receptor complex		0.4 nM	Porcupine	Phase-I	(23)
<b>OMP-18R5</b>	Wnt-receptor complex	-	-	Anti-Frizzled antibody	Phase I	(16)
<b>F8CRDhFc</b>	Wnt-receptor complex	-	1-2 nM	Sequesters Wnts		(8)
<b>OMP-54F28</b>	Wnt-receptor complex	-	-	Sequesters Wnts	Phase I	(8)
<b>WIF1-Fc and sFRP-Fc</b>	Wnt-receptor complex	-	-	Wnt ligands	-	(19)
<b>Wnt-1 antibody</b>	Wnt-receptor complex	-	-	Wnt-1	-	(17, 27, 37)
<b>Wnt-2 antibody</b>	Wnt-receptor complex	-	-	Wnt-2	-	(38, 39)
<b>Wnt-10b antibody</b>	Wnt-receptor complex	-	-	Wnt-10b	-	(27)
<b>3289-8625</b>	β-catenin-destruction complex		12.5 μM	Blocks PDZ domain of Dvl	Preclinical	(14)
<b>FJ9</b>	β-catenin-destruction complex		>100 μM	Interaction between FZD7 and DVL-PDZ domain	Preclinical	(12)
<b>NSC668036</b>	β-catenin-destruction complex		-	Blocks PDZ domain of Dvl	Preclinical	(6)
<b>IWR-1</b>	β-catenin-destruction complex		0.18 μM	Tankyrase 1,2	Preclinical	(4)
<b>JW55</b>	β-catenin-destruction complex		7.3 μM	Tankyrase 1,2	Preclinical	(2, 35)
<b>XAV939</b>	β-catenin-destruction complex		11 nM/ 4 nM	Tankyrases1,2	Preclinical	(20)
<b>PFK115-584</b>	β-catenin/ TCF transcription		< 1μM	Inhibits association between Tcf4 and β-catenin	Preclinical	(22)
<b>CGP049090</b>	β-catenin/ TCF transcription		< 1μM	Inhibits association between Tcf4 and β-catenin	Preclinical	(22)
<b>iCRT3</b>	β-catenin/ TCF transcription		0.14 μM	Tcf4 and β-catenin interaction	Preclinical	(13)
<b>iCRT5</b>	β-catenin/ TCF transcription		-	Tcf4 and β-catenin interaction	Preclinical	(13)
<b>iCRT14</b>	β-catenin/ TCF transcription		-	Tcf4 and β-catenin interaction	Preclinical	(13)
<b>PNU-74654</b>	β-catenin/ TCF transcription		-	Tcf4 and β-catenin interaction	Preclinical	(34)
<b>2,4-diaminoquinazoline series</b>	β-catenin/ TCF transcription		0.22 μM (16K compound)	Tcf4 and β-catenin interaction	Preclinical	(7)
<b>BC21</b>	β-catenin/ TCF transcription		5 μM	Tcf4 and β-catenin interaction	Preclinical	(33)
<b>ICG-001</b>	β-catenin/ TCF transcription		3 μM	β-catenin / CBP interaction	Preclinical	(1, 9)